Halozyme Therapeutics (HALO) Tops Q4 EPS by 3c; Guides FY15 Revs
Tweet
Share
E-mailGet Alerts HALO Hot Sheet
Price: $111.74 +1.88%
EPS Growth %: +30.8%
Financial Fact:
Cost of product sales: 9.13M
Today's EPS Names:
VIVO, OCCI, ALZN, More
EPS Growth %: +30.8%
Financial Fact:
Cost of product sales: 9.13M
Today's EPS Names:
VIVO, OCCI, ALZN, More
Join SI Premium – FREE
Halozyme Therapeutics (NASDAQ: HALO) reported Q4 EPS of ($0.04), $0.03 better than the analyst estimate of ($0.07). Revenue for the quarter came in at $30.38 million versus the consensus estimate of $25.6 million.
Halozyme Therapeutics sees FY2015 EPS of $85.00-$95.00, versus the consensus of $97.70.
For earnings history and earnings-related data on Halozyme Therapeutics (HALO) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
- Element Solutions (ESI) PT Lowered to $47 at UBS, Buy Rating Maintained
- Redburn upgrades Southwest, stays bullish on Delta and United
Create E-mail Alert Related Categories
Earnings, GuidanceRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
